Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
11,512
Total Claims
$1.8M
Drug Cost
1,284
Beneficiaries
$1,417
Cost/Patient
Risk Score Breakdown 6/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-95%
Opioid rate vs peers
0.1% vs 2.6% avg
+33%
Cost per patient vs peers
$1,417 vs $1,068 avg
+59%
Brand preference vs peers
14.3% vs 9.0% avg
Opioid Prescribing
0.1%
Opioid Rate
14
Opioid Claims
$47
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,608 claims · $1.6M
Generic: 9,627 claims · $222K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 160 | $260K |
| Semaglutide | 70 | $194K |
| Apixaban | 81 | $118K |
| Dapagliflozin Propanediol | 65 | $94K |
| Insulin Glargine,hum.Rec.Anlog | 86 | $86K |
| Semaglutide | 49 | $82K |
| Linagliptin | 54 | $82K |
| Dulaglutide | 30 | $78K |
| Sitagliptin Phosphate | 43 | $72K |
| Insulin Degludec | 54 | $57K |
| Insulin Detemir | 34 | $55K |
| Insulin Glargine,hum.Rec.Anlog | 37 | $39K |
| Icosapent Ethyl | 30 | $27K |
| Rivaroxaban | 17 | $25K |
| Denosumab | 14 | $24K |
Prescribing Profile
Patient Profile
74
Avg Age
59%
Female
1.66
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data